ABSTRACT
Children with spastic cerebral palsy (CP) are characterized by altered muscle growth, secondary to the pathological neural input to the muscular system, caused by the primary brain lesion. As a result, their medial gastrocnemius is commonly affected and is characterized by altered macro and microscopic muscular alterations. At the macroscopic level, the muscle volume (MV), anatomical cross-sectional area of the muscle belly (Belly-CSA), muscle belly length (ML), and the intrinsic muscle quality are reduced. At the microscopic level, the cross-sectional area of the fiber (Fiber-CSA) is characterized by an increased within-patient variability (coefficient of variation (CV)), the fiber type proportion is altered and capillarization is reduced. However, the relations between the muscular alterations at the macro- and microscopic level are not yet known. Therefore, this cross-sectional study integrated macro- and microscopic parameters of the medial gastrocnemius in one cohort of young ambulant children with CP and age-matched TD children, and explored how deficits in macroscopic muscle size are associated with alterations at the microscopic level. A group of 46 children with CP (median age 5.4 (3.3) years) and a control group of 34 TD children (median age 6.3 (3.4) years), who had data on microscopic muscular properties (defined through the histological analyses of muscle biopsies), as well as macroscopic muscle properties (defined by 3D freehand ultrasound) were included. We defined Pearson or Spearman correlations, depending on the data distribution. The macroscopic muscle size parameters (MV, Belly-CSA, ML) showed significant moderate correlations (0.504-0.592) with the microscopic average Fiber-CSA in TD and CP. To eliminate the common effect of anthropometric growth at the macro- as well as microscopic level, the data were expressed as deficits (i.e. z-scores from normative centile curves or means) or were normalized to body size parameters. A significant but low correlation was found between the z-scores of MV with the z-scores of the Fiber-CSA (r=0.420, p=0.006). The normalized muscle parameters also showed only low correlations between the macro- and microscopic muscle size parameters, namely between Belly-CSA and Fiber-CSA, both in the TD (r=0.408, p=0.023) and the CP (ρ=0.329, p=0.041) group. Explorations between macroscopic muscle parameters and other microscopic muscle parameters (capillary density, capillary to fiber ratio, and fiber type proportion) revealed no or only low correlations. These results highlighted the complexity of the interacting network of intrinsic muscle structures, with mainly low associations between the macro- and microstructural level, and it remains unclear how alterations in microscopic muscle structures contribute to the macroscopic muscle size deficits in children with CP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by an Internal KU Leuven grant 3D-MMAP (C24/18/103), and by funding from the Research Foundation Flanders (FWO) for the FWO research projects G0B4619N and G084523N, and the FWO research fellowship to co-author IV (1188923N).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethical Committee of the University Hospitals of Leuven gave ethical approval for this work (S61110 and S62645).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The datasets generated for this study can be found in the Research Data Repository (RDR) of the KU Leuven at …. (doi-link will be uploaded when paper is accepted)